Recent Updates
Recently added Catalysts
ARWR Positive Sentiment

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Tuesday, September 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arrowhead Pharmaceuticals has released interim topline data from its Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNAi therapeutic. This treatment aims to address mixed hyperlipidemia associated with atherosclerotic cardiovascular disease by silencing PCSK9 and APOC3. The results indicate a promising advancement in the management of this condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • Interim data shows promising results for ARO-DIMER-PA.
  • First dual-functional RNAi therapeutic targeting mixed hyperlipidemia.
  • Potential to address atherosclerotic cardiovascular disease effectively.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+396%
120-day peak, hindsight
Typical move
2.4%
average across 5 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
Plozasiran
Phase 3 · Hypertriglyceridemia

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC

Frequently Asked Questions

What is ARO-DIMER-PA?

ARO-DIMER-PA is an investigational RNA interference therapeutic targeting mixed hyperlipidemia.

What condition does ARO-DIMER-PA aim to treat?

It aims to treat atherosclerotic cardiovascular disease due to mixed hyperlipidemia.

What were the results of the clinical trial?

The interim topline data from the Phase 1/2a trial showed promising results.

Which proteins does ARO-DIMER-PA target?

It targets proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3).

ShareAdd on Google
Tags: ARWR Viatris Investor Conferences Healthcare Arrowhead Pharmaceuticals ARO-DIMER-PA RNAi therapeutic mixed hyperlipidemia ASCVD
Last updated: Sep 15, 2026

Biotech snapshot

Cash runway
$1602M liquidity · $59M/mo burn
~26 mo
Minimal dilution risk
Lead asset
PlozasiranPhase 3
Hypertriglyceridemia →

Catalyst track record

+396%
best trade around ARWR's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ARWR.

See every catalyst's timing & PoA →